Perrigo (NYSE:PRGO) Upgraded by Wall Street Zen to "Buy" Rating

Key Points

• Wall Street Zen upgraded Perrigo from “hold” to “buy,” although the broader analyst consensus remains “Hold” with a $19.33 price target.
• Perrigo reported quarterly EPS of $0.50, exceeding the $0.39 estimate, while revenue matched forecasts at $1.02 billion but declined 3.1% year over year.
• Institutional investors own 95.91% of Perrigo’s shares, with several funds—including Bank of America and Handelsbanken Fonder—recently increasing their positions.

Perrigo (NYSE:PRGO - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday.

A number of other research analysts have also recently commented on the stock. Weiss Ratings raised shares of Perrigo from a "sell (d-)" rating to a "sell (d)" rating in a report on Thursday. Zacks Research raised shares of Perrigo from a "strong sell" rating to a "hold" rating in a report on Monday, April 27th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $19.33.

Perrigo Trading Up 2.3%

Shares of PRGO opened at $12.83 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.59 and a current ratio of 2.32. Perrigo has a 52-week low of $9.23 and a 52-week high of $24.60. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -1.03, a PEG ratio of 1.31 and a beta of 0.51. The business's fifty day moving average is $10.62 and its 200-day moving average is $11.54.

Perrigo (NYSE:PRGO - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.11. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. Perrigo had a positive return on equity of 11.25% and a negative net margin of 41.85%.Perrigo's revenue for the quarter was down 3.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.06) EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities analysts anticipate that Perrigo will post 2.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Perrigo

Several large investors have recently bought and sold shares of PRGO. Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in shares of Perrigo during the second quarter valued at about $4,066,000. Handelsbanken Fonder AB increased its stake in shares of Perrigo by 20.7% in the second quarter. Handelsbanken Fonder AB now owns 50,200 shares of the company's stock valued at $522,000 after buying an additional 8,600 shares during the period. GAMMA Investing LLC raised its holdings in Perrigo by 58.3% in the 2nd quarter. GAMMA Investing LLC now owns 14,733 shares of the company's stock valued at $153,000 after buying an additional 5,427 shares during the last quarter. Bank of America Corp DE raised its holdings in Perrigo by 25.5% in the 1st quarter. Bank of America Corp DE now owns 1,568,598 shares of the company's stock valued at $16,847,000 after buying an additional 318,248 shares during the last quarter. Finally, RBF Capital LLC acquired a new stake in Perrigo during the 1st quarter worth approximately $1,933,000. 95.91% of the stock is currently owned by institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo's focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo's operations span research and development, manufacturing, quality assurance and global distribution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source